This review summarizes studies on humoral immune responses against tumor-associated
antigens (TAAs) with a focus on antibody frequencies and the potential diagnostic …

Prostate cancer (PC) is the second most common form of cancer in men worldwide.
Biomarkers have emerged as essential tools for treatment and assessment since the …

Purpose Sipuleucel-T, the first FDA-approved autologous cellular immunotherapy for
treatment of advanced prostate cancer, is manufactured by activating peripheral blood …

In order to grow within an immunocompetent host, tumour cells have evolved various
strategies to cope with the host's immune system. These strategies include the …

Proteomics discovery leads to a list of potential protein biomarkers that have to be
subsequently verified and validated with a statistically viable number of patients. Although …

Over the past decade, it has been demonstrated that cancer is immunogenic, and multiple
tumor antigens have been identified in cancer patients. It is now possible to potentially …

Purpose: Prostate tumors express antigens that are recognized by the immune system in a
significant proportion of patients; however, little is known about the effect of standard …

Background: Although prostate-specific antigen (PSA) is a prototypic biomarker for prostate
cancer, it has poor specificity. Expression of α-methylacyl-CoA racemase (AMACR), which is …

Protein microarrays contain a defined set of proteins spotted and analyzed at high density,
and can be generally classified into two categories; protein profiling arrays and functional …

From the earliest days in the field of tumor immunology three questions have been asked: do
cancer cells express tumor-specific antigens, does the immune system recognize these …